Dow Jones
37.899,40 +164,29 (+0,44%) Nasdaq
15.922,02 +37,00 (+0,23%) Nikkei 225
38.471,20 -761,60 (-1,94%) EUR/USD
1,0634 +0,0008 (+0,07%) Bitcoin EUR
59.152,78 -511,61 (-0,86%) CMC Crypto 200
885,54 0,00 (0,00%)
argenx SE (0QW0.L)
- GlobeNewswire
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated patients were responders on the MG-ADL scale compared to 30% of placebo patients after one treatment cycle Amsterdam, The Netherlands —Sep. 21, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno
- GlobeNewswire
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administrationEuropean Commission (EC) decision on marketing authorization application (MAA) expected within approximately 60 days Amsterdam, The Netherlands—September 15, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm
- GlobeNewswire
argenx to Present at Upcoming Investor Conferences
August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in September: Citi's 18th Annual BioPharma Conference. Fireside chat on Wednesday, September 6, 2023 at 4:20 p.m. ET in Boston, MA.Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2
